Block Money Billionaires Spreads The Word On Patented AIDS Cure

March 16, 2009 - PRLog -- US Patent Claiming CURE for AIDS (USP # 5,676,977)"

In October 1977, the United States patented a "method for curing AIDS', US Patent # 5,676,977. The product is called TETRASIL/IMUSIL and is a one-time injection/infusion that eliminates bacterial pathogens in the blood system of an individual. It is this cheap and effective cure for AIDS that is the subject of my presentation.

As a 29-month recipient of this one time injection, I further submit that we have an effective and cheap remedy for AIDS that is ready now. Our goal in bringing this information to the international community is to serve as aconduit for the necessary global "double blind" efficacy clinical trials of this U.S. patented CURE for AIDS.
 

...Marantech has identified a number of Electron Jumping Compounds (EJCs) that have been found in independent laboratory testing to exhibit
antimicrobial activity. However, to date the bulk of Company testing of EJCs for pharmacological safety and efficacy has centred on tetrasilver
tetroxide, a multivalent metal oxide also known as Tetrasil..

Independent laboratory and clinical testing indicates that Tetrasil molecules selectively target and kill rapidly proliferating organisms (e.g., cancer cells and pathogenic micro-organisms) through a multitude of nano-level electrical discharges followed by physical combination (chelation), while leaving normal tissues generally unaffected. The unusual suspected kill method may thwart the development of pathogens resistant to Tetrasil therapy.

Antimicrobial Activity: It has been known for several years that Tetrasil is a potent antimicrobial agent that kills a broad spectrum of viruses, fungi, algae and bacteria (including drug resistant strains) in vitro at concentrations that have been certified safe by the EPA for usage in swimming pools ("EPA Levels").

Recent clinical studies commissioned by Marantech and conducted by Exetec Labs in Honduras, indicate that topically applied Tetrasil can
lead to dramatic improvements in such infection-caused skin conditions as acne, cold sores, herpes lesions, conjunctivitis, chickenpox,
shingles, dermal tuberculosis and ringworm.

Moreover, building on earlier informal testing against systemic infections (including Candida albicans, dysentery and AIDS), Exetec has
been commissioned to conduct clinical studies of Tetrasil as an intravenous treatment for AIDS and tuberculosis.

One may contact Dr. Antelman through the Weizmann Institute in Israel or through Antelman Technologies, POB 382, Rehovat, Israel. Email contact:
impy@netvision.net.il

For information about Tetrasil and Imusil, you are invited to look up the Marantech website at http://www.Marantech.com
Marantech is the company presently supplying Imusil.